✦ Over the past five years, biosimilars created competition that resulted in savings of $9.8 billion. That’s according to Amgen Inc.’s 2021 Biosimilar Trends Report, its eighth edition. The therapies also have the potential to save people out-of-pocket costs of $238 million in the nine classes in which the agents have been approved. The drugs are launching with wholesale acquisition costs that are generally between 15% and 37% less than those of their reference products.
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed DosesREAD MORE
New FDA Approvals: FDA Expands Patient Population of Takeda’s HyQviaREAD MORE